OTX-DED met the primary endpoint in a phase 2 trial investigating the ophthalmic insert for safety and efficacy in the short-term treatment of dry eye disease, according to a press release from Ocular Therapeutix.
In the randomized, double-masked, vehicle-controlled, multicenter trial, OTX-DED (dexamethasone intracanalicular ophthalmic insert) showed statistically significant improvement in bulbar conjunctival hyperemia, the primary endpoint.
One hundred sixty-six subjects were enrolled in the modified intent-to-treat population and were randomly assigned to receive OTX-DED 0.2 mg, OTX-DED 0.3